Levi & Korsinsky, LLP announces that a ABBV class action lawsuit has been filed on behalf of investors who purchased AbbVie Inc. (ABBV) securities between October 25, 2013 and September 18, 2018. For more on the ABBV Lawsuit please contact us today.
According to the lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) AbbVie’s strategy to increase the sales growth of its blockbuster drug, HUMIRA, relied in part upon illegal kickbacks and unlawful sales and marketing tactics; (2) such practices would foreseeably lead to heightened scrutiny by State governments and agencies; and (3) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
If you suffered a loss in you have until November 20, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.